What is a stock summary page? Click here for an overview.
Business Description
Leap Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US52187K2006
Description
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 177.63 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 26.6 | |||||
| 3-Year EPS without NRI Growth Rate | 27 | |||||
| 3-Year FCF Growth Rate | 26.8 | |||||
| 3-Year Book Growth Rate | -57.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.56 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.21 | |||||
| 9-Day RSI | 43.91 | |||||
| 14-Day RSI | 40.94 | |||||
| 3-1 Month Momentum % | -92.7 | |||||
| 6-1 Month Momentum % | -89.72 | |||||
| 12-1 Month Momentum % | -90.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.41 | |||||
| Quick Ratio | 3.41 | |||||
| Cash Ratio | 3.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -63.1 | |||||
| Shareholder Yield % | -365.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -131.28 | |||||
| ROA % | -103.49 | |||||
| ROIC % | -3951.54 | |||||
| 3-Year ROIIC % | 25839.51 | |||||
| ROC (Joel Greenblatt) % | -18000.26 | |||||
| ROCE % | -136.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.29 | |||||
| Price-to-Tangible-Book | 0.29 | |||||
| EV-to-EBIT | 0.51 | |||||
| EV-to-EBITDA | 0.51 | |||||
| EV-to-FCF | 0.6 | |||||
| Price-to-Net-Current-Asset-Value | 0.3 | |||||
| Price-to-Net-Cash | 0.3 | |||||
| Earnings Yield (Greenblatt) % | 196.08 | |||||
| FCF Yield % | -550.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Leap Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.701 | ||
| Beta | 0.75 | ||
| 3-Year Sharpe Ratio | -0.2 | ||
| 3-Year Sortino Ratio | -0.3 | ||
| Volatility % | 125.91 | ||
| 14-Day RSI | 40.94 | ||
| 14-Day ATR (€) | 0.072261 | ||
| 20-Day SMA (€) | 0.2452 | ||
| 12-1 Month Momentum % | -90.09 | ||
| 52-Week Range (€) | 0.094 - 4.54 | ||
| Shares Outstanding (Mil) | 41.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Leap Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Leap Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Leap Therapeutics Inc Frequently Asked Questions
What is Leap Therapeutics Inc(FRA:5MC)'s stock price today?
The current price of FRA:5MC is €0.19. The 52 week high of FRA:5MC is €4.54 and 52 week low is €0.09.
When is next earnings date of Leap Therapeutics Inc(FRA:5MC)?
The next earnings date of Leap Therapeutics Inc(FRA:5MC) is 2025-05-13 Est..
Does Leap Therapeutics Inc(FRA:5MC) pay dividends? If so, how much?
Leap Therapeutics Inc(FRA:5MC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers